Nicole J Walker

🚀 Attention Investors and Healthcare Leaders! 🚀 R3i are thrilled to celebrate StratifiCare™ Pte. Ltd.'s CEO, Anthony Chua, who just landed in Dallas, Texas, to accelerate the progress of two revolutionary personalized medicine diagnostics: 🌟 Stratifiden - The world's first severe dengue prognostic that reduces unnecessary hospitalization by 67%, easing the emotional and financial burden on families. 🌟 Stratifirey - The world's first liver cancer diagnostic that predicts patient response to Y90 RE treatment, allowing clinicians to make informed decisions and reduce the agonizing 3 to 6-month wait for results. StratifiCare's journey is a testament to perseverance and innovation. To develop these groundbreaking products, it secured $35M in non-dilutive capital and less than $1M in venture capital. Anthony Chua's unwavering determination teaches us the power of persistence and the impact of every step forward. A special thank you to David Jacobson for welcoming StratifiCare™ Pte. Ltd. into our Texas triangle and the SMU Cox School of Business community. 💡 Investors and hospital administrators, this is your chance to be part of a transformative journey in personalized medicine. Reach out and learn how you can support and benefit from these pioneering advancements. Together let's accelerate impact 💡 NUS Overseas Colleges National University of Singapore Singapore Economic Development Board (EDB) #HealthcareInnovation #PersonalizedMedicine #DengueDiagnostic #LiverCancerDiagnostic #StratifiCare #InvestmentOpportunities #HealthcareLeaders #MedicalBreakthroughs #Valuebasedcare Enterprise Singapore

25

Big congrats to our outstanding rising clinical research stars and global health practitioners at IGHS, UCSF! After months of dedicated hard work, we've all completed our qualifying oral exams. I believe these projects hold the potential to lead to the development of new healthcare technologies, services, or interventions that address pressing global health issues and aid underserved populations. The breadth of our research is evident in the diverse range of global health issues we explored, including but not limited to: 1. Women's empowerment and reintegration programs. 2. Telehealth systems for Native American children with complex medical needs. 3. Performance of COVID-19 exposure notification systems. 4. Mental health interventions during natural disasters in low- and middle-income countries. 5. Cancer screening and treatment access in underserved communities. 6. HIV care and support services. 7. Predictors of disease severity in pediatric febrile illnesses. 8. Cost-effectiveness analyses of various interventions (malaria detection, CAR T-cell therapy, cervical cancer screening). 9. Social media analysis of tobacco product marketing strategies. 10. Pediatric emergency triage tools for resource-limited settings. 11. The impact of food insecurity on mental health. 12. Acculturation, diet quality, and their connection to childhood obesity. 13. Nursing perspectives on COVID-19 pandemic interventions. This wide range of topics underscores the multifaceted nature of global health challenges and the critical need for innovative, interdisciplinary solutions. Furthermore, cost-effectiveness analyses, cost-of-illness studies, and implementation studies can inform strategies for sustainable and scalable solutions.

36

13 Comments

Why Physicians Should Consider Investing in HealthTech Venture Funds As a physician deeply entrenched in the world of healthcare, I've observed firsthand the transformative impact of technology on our industry. From telemedicine to AI-driven diagnostics, the pace of innovation is staggering—and it’s only accelerating. Today, I want to share why we, as physicians, should consider investing in HealthTech venture funds 👇 - Driving Innovation: By investing in HealthTech funds, we're not just placing capital; we're actively propelling the future of medicine. Our investment helps fund the technologies that could one day revolutionize patient care and our daily medical practices. - Insider Expertise: Who better to understand the potential of a new medical technology than those of us in the field? Our clinical experience enables us to assess the feasibility and potential impact of innovations, making us well-suited to make informed investment decisions. - Spreading Impact Beyond Practice: While we impact lives daily through direct patient care, investing in a HealthTech fund allows us to extend our influence by supporting solutions that reach a global patient base, potentially benefiting millions. - Financial Returns: HealthTech is one of the fastest-growing sectors, and investing in this area offers a valuable opportunity for substantial financial returns. Diversifying our portfolios beyond traditional stocks and real estate into venture funds can offer a unique balance of risk and reward. - Personal and Professional Growth: Engaging with the startup and tech ecosystem exposes us to new ideas and business strategies, broadening our horizons beyond clinical practice. This can lead to professional growth and networking opportunities that may not otherwise arise. I encourage my fellow healthcare professionals to look into HealthTech venture funds as a way to participate in the broader spectrum of healthcare innovation. Our expertise and capital can play a crucial role in shaping the future of the industry. ---- To join our vibrant community of 2,000+ healthtech experts and thought leaders, click the link in my profile bio.

19

The role of AI and new technology to aid cardiology “As cardiology starts to face staffing shortages and continued decreases in CMS payments, Biga believes technology advances need to be leveraged in cardiology to help improve outcomes, make workflows more efficient to do more with less, and to help cut costs.” “Many of the solutions that can help were displayed on the expo floor, including telehealth and real-time remote monitoring systems. "I think this area will experience an explosion in use," Biga said. Another major area that will likely see an explosion of use is artificial intelligence (AI). She said AI will begin playing a rapidly growing role in cardiology in the coming years to augment cardiologists and other clinical staff. And not just on the front lines of patient care, but also in the back offices where AI will play a growing role in IT systems, smoothing workflow, analytics, automated quality metrics capture and many other areas. "We must use AI to reduce administrative burdens and improve patient outcomes," Biga explained. “

17

1 Comment

This article by the WSJ is critically important for public health officials and HealthTech entrepreneurs to internalize. We need multiple solutions for patients to move towards post GLP-1 usage. These solutions need to be easy to implement, non-disruptive to daily life and focused on caloric restriction , lifestyle change and muscle gain. Too many startups are still focused on GLP-1 prescription and delivery. Not enough people focused on the next stage of the weight management journey. As the Journal states, the benefits of the GLP-1 craze are only going to be successful long term if the transition off of them is successful. Otherwise, we risk unforeseen, long term consequences to a large group of patients stuck on GLP-1's with no healthy way to transition off. https://lnkd.in/dYBd3HaN Meghan FitzGerald James Stearns Dominic Perks John LaMattina Raju Kucherlapati

29

2 Comments

"“The detection of AFib significantly improved over the past two decades, primarily due to advancements in technology, changes in clinical practice and increased awareness,” the authors wrote. “Approximately a third of patients with AFib are asymptomatic, and enhanced detection over time may lead to increased lifetime risk of diagnosed AFib. Another possible reason is the global increase in life expectancy.” Meanwhile, AFib patients faced high lifetime risks of developing heart failure (41%) or experiencing a stroke (21%). The lifetime risk of an AFib patient suffering a myocardial infarction was 12%. “Our findings encourage greater attention to secondary prevention of heart failure after AFib, and in line with a recent report from the National Heart, Lung, and Blood Institute, relevant future initiatives include development of non-anticoagulant pharmacotherapies, effective implementation of weight loss and risk factor modification, and designing successful programs for cardiac rehabilitation. As AFib is a common arrhythmia, a lower incidence of complications may reduce the future economic costs in healthcare.”" MedTech Innovator American Heart Association Heart Rhythm Society American College of Cardiology #epeeps LSI

44

2 Comments

As the discourse shifts from models to compound AI systems / agents, we need better AI benchmarks to evaluate multi-modal and multi-step task performance, especially in healthcare and life sciences. When we wrote the first paper demonstrating ChatGPT's performance on the USMLE, we chose the US Medical Licensing Exam as a benchmark for accessibility, speed, and ease. This benchmark was never intended to represent AI model performance on real-world clinical tasks. Today, I still see so many research teams and startups using benchmarks (like the USMLE) that are ill-fitted for assessing the true clinical or scientific performance and utility of the models they are developing for real-world contexts. Benchmark development may be seen as a "less sexy" area of research, but it is of paramount importance. Years after the rise of the transformer, we still lack adequate benchmarks for so many single-step tasks in biomedicine. With compound AI systems (i.e., architectures that integrate multiple AI models to perform complex tasks) emerging, we need new benchmarks for agentic behaviors. I'd argue that developing an agent with novel capabilities without at least proposing a companion benchmark (if an industry standard does not yet exist) may hinder the adoption of said agent, especially for high-stakes workflows. Designing more benchmarks that capture/simulate real-world clinical and scientific workflows will help us mitigate the major discrepancies observed between in silico and in vivo performance and better support safe + effective deployment of AI in biomedicine. There are already brilliant people focused here, and we need more. DMs are open if you're researching or working in this area of multi-step/multi-modal benchmarking in healthcare and life sciences! #healthcare #ai #artificialintelligence #generativeai

100

18 Comments

Among the top 50 Life science startups, a whopping 46 (92%) were therapeutics companies, 3 (6%) were diagnostics companies, and 1 (2%) was a life sciences tools company (10X genomics). Major indication areas included oncology, immunology, CNS diseases, and infectious diseases. Oncology was the most common lead therapeutic area (16 companies, 34.78%), followed by rare diseases (13 companies, 28.26%). #Biotech #lifescience

1

“Cardiology continues to have the second largest number of clinical artificial intelligence (AI) algorithms cleared by the U.S. Food and Drug Administration, trailing only radiology. The FDA's latest update covers all AI approvals through May 2024. There are now 122 FDA-cleared AI algorithms specific to cardiology. This makes up 14% of the 882 clinical AI algorithms now on the U.S. market. The new FDA numbers include market clearances up to March 31, 2024. The first approval of a clinical AI algorithm was in 1995. The first cardiology specific algorithm was for HeartFlow FFR-CT in 2016. That algorithm was also the first AI to be included in a cardiology guideline when the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain was released.” MedTech Innovator American Heart Association #epeeps Heart Rhythm Society American College of Cardiology LSI Capital Factory Company Ventures MedTech Strategist Health Wildcatters Techstars

49

How do we minimize the number of protocol amendments and increase the operational feasibility of our clinical trials? This article below points out the benefits of using data, conversations and real world data to enhance the feasibility of the protocol design and inclusion/exclusion criteria: 1) Are we being too strict on our criteria in order to "control" for data variability? 2) Do are criteria allow for the intended patient population in the real world (if not, they need to) 3) How realistic is your design in how the study sites actually work? How they see and treat patients? How is your company ensuring the design meets these requirements? https://lnkd.in/gzJzFd-3

4

1 Comment

lol How is AI weaving its way deeper in to healthcare….🤔 As we navigate the evolving landscape of healthcare, the conversation around AI often gravitates towards its potential risks and downsides. However, there is also a different narrative—one where AI serves as a transformative tool for specialists making critical decisions about their patients’ and clients’ care. While some may fear that AI aims to replace healthcare professionals, the truth is far from that. AI is not about replacing the invaluable human touch that specialists and prodessionals provide, nor is it merely about speeding up processes. Instead, it’s about augmenting their capabilities, offering new perspectives, and providing a deeper understanding of each individual’s unique symptoms or scenario. AI tools like the ones we use at FirstHx empower regulated healthcare professionals and physicians with advanced insights and clarity. They offer an array of perspectives on how symptoms can be indicators or catalysts for various conditions, ultimately helping guide the professionals to make decisions around next steps in treatment or advice. This technology enables more focused and individualized care, ensuring that every action is tailored to the specific needs of the patient. By leveraging AI, healthcare professionals gain new tools that enhance their ability to serve their populations more effectively. It’s not about replacement; it’s about empowerment and improvement. AI in healthcare is about giving specialists the vision and clarity to make more informed, precise decisions, leading to better outcomes for all. Check out how we are assisting professionals strive for optimal outcomes at First HX. Here is our founder Mark Benaroia, MD, MHSc, FRCPC breaking down how the company and technology came to fruition in his latest appearance on the Maker’s Bar Podcast. https://lnkd.in/grna7gqf #AIinHealthcare #HealthTech #Innovation #PatientCare #HealthcareProfessionals #FirstHx #FutureOfHealthcare #mentalhealth #behaviouralhealth #AI #physician #psychology #BCBA #socialwork #medical

7

4 Comments

Takeda's CEO's annual letter hits on some key themes that many biopharma CEO's are converging on: value-based care, price transparency, breaking up the middlemen, and driving healthcare access and equity. "For several years I have been outlining Takeda’s thinking on health equity—including advocating for a transition to value-based health care that pays for outcomes and care quality, emphasizing the need to prepare for the next pandemic by ensuring global vaccine equity and explaining how the protection of intellectual property rights is essential to incentivize investment in R&D. One area where we would like to see greater progress this year is pharmacy benefit managers reform. We support efforts in Congress to delink rebates from list prices or wholesale acquisition cost. It is a complex system, but the bottom line is that the current system creates misaligned incentives that ultimately result in higher costs for the system and higher out-of-pocket costs for patients. One potential way to address these challenges is through greater transparency. Transparency at the point of purchase for patients would empower them to make decisions knowing exactly what their costs will be. This could lower costs for the entire system by building in greater pricing accountability along the chain so that no stakeholder can benefit from the inefficiencies that result in the prices that patients pay today." At COEUS, we are working with the world's leading biopharma companies to help transition them from a broken FFS model towards value-based care. We have built the world's leading platform that hosts the biggest CGT commercial launches, and rapidly moving into Oncology, Obesity/ Diabetes, and beyond. 1. Enabling Value-Based Healthcare: Our solution facilitates the transition to value-based healthcare by providing a powerful tool for creating and managing contracts that pay for outcomes and care quality. 2. Enhancing Transparency: By aggregating disparate healthcare data from various sources, our platform provides unprecedented transparency into the entire healthcare ecosystem. This empowers payers, providers, and patients to make informed decisions and helps stakeholders across the value-chain to tie price and value to therapeutic outcomes. 3. Driving Innovation: Our platform's ability to evaluate complex rules for value-based contracts, real-world evidence studies, and health equity measurements fosters innovation in the pharmaceutical industry. By providing a tool to measure the impact of new solutions, we help companies drive medical advancements while ensuring equitable access. 4. Improving Access and Affordability: Our solution helps identify areas where access and affordability can be improved without compromising innovation. By providing data-driven insights into the effectiveness of various interventions, we enable stakeholders to make informed decisions that benefit patients and the healthcare system as a whole. Visit https://coebra.ai/.

10

By leveraging extensive biological data and AI's computational power, we're seeing a revolution in how quickly and efficiently new therapies are developed. This fusion of data science and biology can help accelerate the discovery phase and enhance the precision of targeting specific diseases. Our focus at Envision Pharma Group remains on the seamless integration of anonymized, historical, and predictive data. This approach not only maintains stringent data privacy standards but also propels us towards more groundbreaking, patient-centric solutions. Harnessing this data efficiently and securely means more rapid advancements from the lab to the patients who need them most. By collaborating across sectors, sharing insights, and challenging our conventional workflows, we can continue driving innovation and deliver results that truly matter. https://lnkd.in/eSVQEVpz

25

…and private equity wants in on the action. Well that makes sense 🙄 Turns out running a hospital is very, very hard. A 4.3% margin is not healthy, even for a non-profit. Payors and pharma continue to point the finger at these “rich” hospitals and complain about market consolidation, 340B, and any number of other phantom problems, but in reality most are just trying to survive. Many of these grievances are gaslighting in its purest form. Those making it work are focused on the basics. The strategic plan has highly pragmatic, common sense initiatives that return a tangible benefit with clear measurable targets as opposed to chasing trendy buzz words. They control labor and they control drug cost. On the pharmacy side, they deeply understand the economics and have an appropriately positioned business minded, strategic pharmacy leader. #pharmacist #pharmacy #hospitals #healthcare https://lnkd.in/g9d9VTcK

20

🤰✨Addressing Inequities in Maternal Care: The Mission of Delfina ✨🤰 "Seeing that patient's anguish and the feeling of letdown, it was a feeling that we had let her down." Learn about the heartbreaking stillbirth that Senan witnessed as a young physician that was the catalyst to Senan deciding to build Delfina. Tech issues on my end will not get in the way of this incredible episode with Senan Ebrahim, MD, PhD the incredible CEO and founder of Delfina! Excuse my lack of video here as we jump in and discuss his journey in using technology to improve global maternal health. He shares his inspiration for getting into healthcare, the challenges he witnessed in prenatal care, and the importance of data-driven clarity and certainty in healthcare. Senan also shares about his previous venture, Hicma Health, and the accomplishments he is proud of. Delfina is focused on solving the maternal health crisis by using data and AI to provide intelligent pregnancy care. One major challenge in the healthcare industry is the data infrastructure, which is often outdated and not interoperable. Delfina aims to provide a maximally interoperable platform that can pull in and deliver data to health plans and providers. The typical experience for a Delfina member includes onboarding through the app, tracking symptoms and vital signs, and engaging with human doulas. The goal is to empower pregnant patients and provide personalized care. Do you have someone you love, that would LOVE this sort of approach to pregnancy care? We cover a lot of ground 🏃‍♂️🏃‍♀️💨💨: 🔴Data-driven clarity and certainty are crucial in healthcare to provide better care for patients, Senan's previous venture, aimed to provide digital health solutions for refugees and vulnerable populations. 🟠Inequities in maternal care, particularly among Medicaid patients, are a public health crisis that needs to be addressed. 🟢Delfina is working to solve these inequities by partnering with Medicaid plans and community-based organizations. The data infrastructure in healthcare is a major challenge, and Delfina aims to provide a maximally interoperable platform to address this issue. 🟡Delfina uses AI and machine learning to improve outcomes in obstetrics and pregnancy care. 🟢The typical experience for a Delfina member includes onboarding through the app, tracking symptoms and vital signs, and engaging with human doulas. 🟤Delfina's future plans include deepening its impact, rigorously measuring outcomes, and scaling to reach every pregnant patient in the United States. Watch the entire episode Digital Health Heavyweights Podcast to hear me pick the brain of an empathetic and brilliant CEO and Founder, and learn about the incredible work that Delfina is doing to impact maternal care worldwide! ▶ https://lnkd.in/dgwD6PHU 👂 https://lnkd.in/dyt3Vvhs

19

3 Comments

A big demand and supply challenge for American - and Canadian, Mexican, UK, EU, Latin America, Africa, Asia, Australia - obesity healthcare. This is a good read by Maya Goldman explaining the problem that exists in the US. Basically, 8,300 certified obesity experts cannot meet more than 2% of the market demand. What's even more important is the need for training existing GPs and obesity experts on the prescription and treatment through GLP-1 drugs like #Ozempic, #Wegovy, #Mounjaro, #Zepbound and a few more that are going to flood the market soon. We at MYND Therapeutics Inc. believe that smartphones, digital health technologies such as digital twins, #AI, digital therapeutics (software-as-therapy) such as MYNDSET can improve access and delivery of digital obesity care, can reduce cost for health systems, can reinvent the physician-patient relationship, can train doctors using immersive technologies like Augmented Reality, Virtual Reality, Extended Reality, can help solve the equity problem that exists in America and other parts of the world, can improve a person's health as much if not more than a drug can but without the same costs and side effects. Digital health can democratise healthcare and digitise medicine - at SCALE. 🧠 P.S. Check out the new MYNDSET Clinician Referral Program (https://lnkd.in/ggcFz7-g) P.P.S. Thank you to Shantanu Gaur for sharing the article. #obesity #training #weightloss #weightmanagement #GLP1 #drugs #digitalhealth #digitaltherapeutics #VR #AR #XR #MXR #impact

1

Synthesis of AI in Healthcare Fireside chat Dear fellow pathfinders, gamechangers, and trailblazers. Here is a brief synopsis of this highly relevant discussion topic I attended at the HeAL conference in Las Vegas last week. How AI is changing our outlook on modern day healthcare Ian Slade, CEO | HPMA; Ravi Tenneti, Senior Vice President; Eddy Pham, CEO | Infortum.io The fireside chat explored how AI transforms modern healthcare. Here are the take aways: As AI becomes a more prominent aspect of healthcare applications and operations, critical thinking for the individual provider who is using the AI is even more important. AI is a tool that can be employed in multiple use cases to solve complex data aggregation and formatting of such data to assist humans in making decisions based on this complex data. It is a tool of augmented intelligence. But clinical judgment and the understanding of basic ethical principles in healthcare remains an integral and irreplaceable part of care. AI provides better predictive analytics compared to humans, but input data may be biased. Understanding the underlying data science principles to recognize these biases in the algorithm and final output is paramount. The data must then be interpreted in the context of the human experience and within our societal values. The slower speed of AI adoption in healthcare is related to the juxtaposition of high value to high risk, as we are working with real life health outcomes. Predictions are never 100%, and safer applications such as claims processing are excellent for faster adoption. Streamlining operations and resulting cost reductions lead to increased value creation. AI in healthcare is an excellent tool of augmented intelligence, but the a) critical evaluation by the human expert, b) a clear definition of a confidence levels for data outputs defined for different risk levels (treatment decisions versus claims processes), and a c) close collaboration of providers and healthcare stakeholders with data scientists are key in the successful integration of AI as a meaningful tool into clinical practice and healthcare as a whole. In the end, the human connection remains at the center of healthcare. We have a duty to protect the autonomy of our patients – the most vulnerable of all stakeholders – and through ongoing open dialogue ensure that they are able to make informed decisions about their health and receive fair, just, and unbiased care. Thank you to the discussion panel Ian Slade, Ravi Tenneti, and Eddy Pham for such an insightful talk! Katharina

14

4 Comments

In an article written by Business Wire, Health For Mankind Company introduces their new solution - DIABIMETRICS™. Dubbed a groundbreaking digital health platform, it’s aimed at transforming diabetes management and bridging health disparities. The platform is focused on serving communities often overlooked by the healthcare system, such as African Americans, Hispanics, and Native Americans. DIABIMETRICS™ offers personalized care plans, virtual coaching, culturally tailored dietary guidance, data-sharing capabilities to enhance patient care, and predictive analytics to identify individuals at risk of complication for proactive health management. It uses advanced algorithms and real-time data integration for seamless connectivity with wearable devices and health apps. It's estimated that through this platform, healthcare providers can make data-driven decisions and potentially save up to $7,900 per patient annually by reducing hospital visits and managing care more effectively! Learn more: https://lnkd.in/dR3yK3fT #DiabetesManagement #HealthEquity #DigitalHealth #MinorityHealth #Innovation

14

1 Comment

🎙️ New Episode Drop on The Best Ideas Win! 🚀 I’m excited to share a not-to-be-missed two-part conversation with Dennis Chornenky, a visionary at the forefront of artificial intelligence (AI) and its transformative role in healthcare and public policy. Dennis, with his notable background as a former senior advisor on AI at the White House and now as the chief AI advisor to UC Davis Health, brings a unique blend of insights on navigating the complexities of AI within the government and healthcare sectors. His work is pivotal in using AI to address societal challenges and driving healthcare towards a future where AI-driven solutions optimize patient care and operational efficiency. 🔗 Tune in to the first of two episodes here: https://lnkd.in/gaBpx7Rm In this enlightening discussion, Dennis dives into: 1. AI and Regulatory Dynamics: The balancing act between regulatory oversight and industry self-regulation. 2. AI Strategy Development: The crucial steps for health systems starting their AI journey, emphasizing the importance of executive education. 3. AI Governance: Unpacking the layers of effective AI governance and the strategic role of a chief AI officer in shaping AI integration. 4. Collaborative Innovations: How overcoming societal polarization through leadership can enhance collaboration and AI adoption in healthcare. This episode is a treasure trove for anyone involved in healthcare, AI technology, or leadership, providing practical insights and strategic advice on embracing AI responsibly and effectively. 👉 Don’t forget to subscribe for more thought-provoking content and join us in these discussions. Share your thoughts or key takeaways in the comments below! #TheBestIdeasWin #AIinHealthcare #HealthcareInnovation #DennisChornenky #Leadership #ArtificialIntelligence #PublicPolicy #Podcast Ryan Paradis Eric Eskioğlu, MD, MBA, FAANS Brian Paradis

11